Suzhou Rigerna Therapeutics' RG002C0106 Injection Supplemental Application Accepted by China's CDE – Class 1 Chemical Drug Enters Regulatory Review
CompanyDrug

Suzhou Rigerna Therapeutics’ RG002C0106 Injection Supplemental Application Accepted by China’s CDE – Class 1 Chemical Drug Enters Regulatory Review

Data from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) show that a supplemental application for RG002C0106 Injection, submitted by Suzhou Rigerna Therapeutics Co., Ltd.…

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot
CompanyDrug

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

InnoCare's TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease
CompanyDrug

InnoCare’s TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled
CompanyDrug

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled

- Advertisement -
Ad image
Haihe Biopharma's Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World's First Oral Paclitaxel Expands into Second Indication in China
Others

Haihe Biopharma’s Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World’s First Oral Paclitaxel Expands into Second Indication in China

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment
CompanyDeals

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA
CompanyDeals

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA

FDA Approves Genentech's Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction
CompanyDrug

FDA Approves Genentech’s Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction

Taienkang Pharma Subsidiary HABKSON Wins NMPA Approval for Diquafosol Sodium Eye Drops – Generic Dry Eye Therapy Enters RMB 228 Million Chinese Ophthalmic Market
CompanyDrug

Taienkang Pharma Subsidiary HABKSON Wins NMPA Approval for Diquafosol Sodium Eye Drops – Generic Dry Eye Therapy Enters RMB 228 Million Chinese Ophthalmic Market

Livzon Pharma Wins Approval for China's First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty
CompanyDrug

Livzon Pharma Wins Approval for China’s First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty

Hybio Pharmaceutical's AI‑Designed Triple Agonist HY3003 Clears FDA IND Filing for Obesity – GLP‑1/GIP/Glucagon Tri‑Target Drug Outperforms Tirzepatide and Retatrutide in Preclinical Weight Loss
CompanyDrug

Hybio Pharmaceutical’s AI‑Designed Triple Agonist HY3003 Clears FDA IND Filing for Obesity – GLP‑1/GIP/Glucagon Tri‑Target Drug Outperforms Tirzepatide and Retatrutide in Preclinical Weight Loss

Gan & Lee's Insulin Aspart Wins Ethiopian Registration – First Rapid‑Acting Insulin Analogue Approved in Africa's Second‑Most‑Populous Nation
CompanyDrug

Gan & Lee’s Insulin Aspart Wins Ethiopian Registration – First Rapid‑Acting Insulin Analogue Approved in Africa’s Second‑Most‑Populous Nation

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio
Others

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

Zhongsheng Pharma's RAY1225 Achieves 22.2% Weight Loss in Phase III REBUILDING‑2 Trial – Biweekly GLP‑1/GIP Dual Agonist Outperforms Tirzepatide Response Rates on Key Thresholds
CompanyDrug

Zhongsheng Pharma’s RAY1225 Achieves 22.2% Weight Loss in Phase III REBUILDING‑2 Trial – Biweekly GLP‑1/GIP Dual Agonist Outperforms Tirzepatide Response Rates on Key Thresholds

Lifotronic Technology's H100Plus HbA1c Testing System Receives FDA 510(k) Clearance – Chinese IVD Company Gains U.S. Market Access for Diabetes Diagnostics
CompanyDrug

Lifotronic Technology’s H100Plus HbA1c Testing System Receives FDA 510(k) Clearance – Chinese IVD Company Gains U.S. Market Access for Diabetes Diagnostics

Hinova Pharmaceuticals' HP515 Phase IIa MASH Data Accepted as AASLD 2026 Late‑Breaking Abstract – THR‑β Agonist Achieves >50% Liver Fat Reduction With No SAEs
CompanyDrug

Hinova Pharmaceuticals’ HP515 Phase IIa MASH Data Accepted as AASLD 2026 Late‑Breaking Abstract – THR‑β Agonist Achieves >50% Liver Fat Reduction With No SAEs

Show More